<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382199</url>
  </required_header>
  <id_info>
    <org_study_id>VB-Ven100-2011-01</org_study_id>
    <secondary_id>R44AG037211</secondary_id>
    <nct_id>NCT01382199</nct_id>
  </id_info>
  <brief_title>Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients</brief_title>
  <official_title>A Phase III Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ventria Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ventria Bioscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to Evaluate the Efficacy and Safety of Recombinant Human
      Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult
      Patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the number of days of antibiotic associated diarrhea during the treatment period</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Ven100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <arm_group_label>Ven100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must meet all of the inclusion criteria listed below at the time of
             enrollment.

               1. Male and female patients 50 years of age and older.

               2. Resident of a participating long term care facility.

               3. Able to consume 30 mL of liquid solution two time per day by mouth or enteral
                  feeding tube.

               4. Patient has had no antibiotics in the 4 weeks preceding enrollment in the study.

               5. Patient has been started on a broad spectrum antibiotic(s) for an infection other
                  than gastroenteritis.

               6. Patient has a life expectancy greater than 6 months.

               7. Patient or health care agent is able and willing to sign a written informed
                  consent.

               8. Patient or caregiver is able and willing to complete diary of daily bowel
                  movement information (number, formed or unformed, time) during any portion of the
                  8 week study.

        Exclusion Criteria:

          1. Patient has an ileostomy.

          2. Patient has a prior history of major gastrointestinal surgery such as partial small
             bowel or colon resection or gastric bypass.

          3. Patient has a history of inflammatory bowel disease.

          4. Patient has a history of chronic diarrhea associated with irritable bowel syndrome or
             other etiologies.

          5. Patient has a history of severe constipation requiring use of enemas or disimpaction
             within 30 days prior to enrollment.

          6. Patient has signs or symptoms of C. difficile infection including diarrhea.

          7. Patient has signs or symptoms of acute or chronic diarrhea.

          8. Patient has known sensitivity or allergy to rice or rice products.

          9. Patient has significant medical problems which in the judgment of the principal
             investigator or medical monitor may interfere with participation in the study.

         10. Patient is not receiving an antibiotic regimen consisting of a broad spectrum
             antibiotic.

         11. Patient has participated in an investigational study using an investigational product
             within 30 days of randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning Huang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ventria Bioscience</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ning Huang, Vice President Research &amp; Development</name_title>
    <organization>Ventria Bioscience</organization>
  </responsible_party>
  <keyword>Antibiotic Associated Diarrhea in Adult Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

